Comparative stability of the bioresorbable ferric crosslinked hyaluronic acid adhesion prevention solutions

Journal of Biomedical Materials Research - Part B Applied Biomaterials

Volumn 101 B, Issue 6, 2013, Pages 1006-1013

  Luu, Hoan My Do ^a   Chen, Angela ^b   Isayeva, Irada S ^a  

^a CENTER FOR DEVICES AND RADIOLOGICAL HEALTH   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

abdominal tissue adhesions (ATA); adhesion; adhesion barriers (AB); enzymatic degradation; FeHA adhesion prevention solution (Intergel ; FeHA APS); ferric crosslinking hyaluronic acid (FeHA); gel; HA clearance; HA digests; half life (t1 2); hexasaccharides (6S); high pressure liquid chromatography (HPLC); hyaluronic acid (HA); hyaluronidase (Hyase); Intergel ; tetrasaccharides (4S)

Indexed keywords

ADHESION BARRIER; ADHESION PREVENTIONS; ENZYMATIC DEGRADATION; FEHA APS); FERRIC CROSSLINKING HYALURONIC ACID (FEHA); HA CLEARANCE; HA DIGESTS; HALF LIVES; HEXASACCHARIDES; HYALURONIDASE (HYASE); TETRASACCHARIDES; TISSUE ADHESION;

ADHESION; GELS; HIGH PRESSURE LIQUID CHROMATOGRAPHY; ORGANIC ACIDS; POLYVINYL ALCOHOLS; TISSUE;

HYALURONIC ACID;

HYALURONIC ACID; HYALURONIDASE; IRON; LYASE; POLYMER;

ARTICLE; CONTROLLED STUDY; CROSS LINKING; ENZYME DEGRADATION; HYDROLYSIS; MOLECULAR WEIGHT; STREPTOMYCES;

ABDOMINAL TISSUE ADHESIONS (ATA); ADHESION; ADHESION BARRIERS (AB); ENZYMATIC DEGRADATION; FEHA ADHESION PREVENTION SOLUTION (INTERGEL®; FEHA APS); FERRIC CROSSLINKING HYALURONIC ACID (FEHA); GEL; HA CLEARANCE; HA DIGESTS; HALF LIFE (T1/2); HEXASACCHARIDES (6S); HIGH PRESSURE LIQUID CHROMATOGRAPHY (HPLC); HYALURONIC ACID (HA); HYALURONIDASE (HYASE); INTERGEL®; TETRASACCHARIDES (4S);

BIOCOMPATIBLE MATERIALS; CROSS-LINKING REAGENTS; DRUG STABILITY; FERRIC COMPOUNDS; GELS; HUMANS; HYALURONIC ACID; HYALURONOGLUCOSAMINIDASE; MATERIALS TESTING; MOLECULAR WEIGHT; SOLUTIONS; TISSUE ADHESIONS;

EID: 84880514903     PISSN: 15524973     EISSN: 15524981     Source Type: Journal    
DOI: 10.1002/jbm.b.32909     Document Type: Article

References (36)

1. Al-Jabri S, Tulandi, T,. Management and prevention of pelvic adhesions. Semin Reprod Med 2011; 29 (2): 130-137.
2. Attard JA, MacLean AR,. Adhesive small bowel obstruction: Epidemiology, biology and prevention. Can J Surg 2007; 50 (4): 291-300.
3. Bruggmann D. TG, Wallwiener M., Munstedt K., Tinneberg H.R., Hackethal A,. Intra-abdominal adhesions: Definition, origin, significance in surgical practice, and treatment options. Dtsch Arztebl Int 2010; 107 (44): 769-775.
4. Van Goo H,. Consequences and complications of peritoneal adhesions. Colorectal Dis 2007; Suppl 2: 25-34.
5. Ray NF, Denton WG, Thamer M, Henderson SC, Perry S,. Abdominal adhesiolysis: Inpatient care and expenditures in the United States in 1994. J Am Coll Surg 1998; 186 (1): 1-9.
6. Ward BC, Panitch A,. Abdominal adhesions: current and novel therapies. J Surg Res 2011; 165 (1): 91-111.
7. Wiseman DM,. Registries for anti-adhesion products? Fertil Steril 2006; 86 (3): 771; author reply 771-772.
8. Wiseman DM,. Registries for anti-adhesion products? Fertil Steril 2006; 85 (4): e7; author reply e8.
9. Kumar SWP, Leaper DJ,. Intra-peritoneal prophylactic agents for preventing adhesions and adhesive intestinal obstruction after non-gynecological abdominal surgery. Cochrane database Syst Rev 2009; 1: CD005080.
10. Zawaneh PN, Putnam D,. Materials in surgery: A review of biomaterials in postsurgical tissue adhesion and seroma prevention. Tissue Eng Part B Rev 2008; 14 (4): 377-391.
11. US Food and Drug administration. Guidance for Resorbable Device For Use in Abdominal and Pelvic Surgery: Guidance for Industry, 2002. Available at: http://www.fda.gov/cdrh/ode/guidance/1356.pdf.
12. Lapcik L, Jr., Lapcik L, De Smedt S, Demeester J, Chabrecek P,. Hyaluronan: Preparation, structure, properties, and applications. Chem Rev 1998; 98 (8): 2663-2684.
13. Laurent T,. The biology of hyaluronan. Introduction. Ciba Found Symp 1989; 143: 1-20.
14. Laurent TC, Fraser JR,. Hyaluronan. FASEB J 1992; 6 (7): 2397-2404.
15. Payan E, Jouzeau JY, Lapicque F, Muller N, Payan JP, Gegout P, Bertin P, Netter P,. Assay of synovial fluid hyaluronic acid using high-performance liquid chromatography of hyaluronidase digests. J Chrom B: Biomed Sci Appl 1991; 566 (1): 9-18.
16. Tokita Y, Okamoto A,. Hydrolytic degradation of hyaluronic acid. Polym Degrad Stabil 1995; 48 (2): 269-273.
17. Roden L, Campbell P, Fraser JR, Laurent TC, Pertoft H, Thompson JN,. Enzymic pathways of hyaluronan catabolism. Ciba Found Symp 1989; 143: 60-76; discussion 76-86, 281-285.
18. Ludowieg J, Vennesland B, Dorfman A,. The mechanism of action of hyaluronidase. J Biol Chem 1961; 236: 333-339.
19. Girish KS, Kemparaju K,. The magic glue hyaluronan and its eraser hyaluronidase: A biological overview. Life Sci 2007; 80 (21): 1921-1943.
20. Isayeva I, Sarkar Das S, Chang A, DeFoe J, Luu H-M, Vorvolakos K, Patwardhan D, Whang J, Pollack, S,. pH Effect on the synthesis, shear properties, and homogeneity of iron-crosslinked hyaluronic acid-based gel/adhesion barrier. J Biomed Mater Res: Part B-Appl Biomater 2010; 95B (1): 9-18.
21. Sall I, Férard G,. Comparison of the sensitivity of 11 crosslinked hyaluronic acid gels to bovine testis hyaluronidase. Polym Degrad Stabil 2007; 92 (5): 915-919.
22. Johns DB, Keyport GM, Hoehler F, diZerega GS,. Reduction of postsurgical adhesions with Intergel adhesion prevention solution: A multicenter study of safety and efficacy after conservative gynecologic surgery. Fertil Steril 2001; 76 (3): 595-604.
23. Huang JWS NJ,), Johns Douglas, B., (, Milford, NJ,), Kronenthal Richard, L., (, Fair Lawn, NJ,); Lifecore Biomedical, Inc. (, Chaska, MN,), assignee. Ionically crosslinked carboxyl-containing polysaccharides for adhesion prevention. United States patent 5532221. 1996.
24. FDA. Lifecore Biomedical GYNECARE INTERGEL Adhesion Prevention Solution, Labeling, Approval Order, Summary of Safety and Effectiveness, November 16, 2001 Premarket application # P99015.
25. Johns DB, Rodgers KE, Donahue WD, Kiorpes TC, diZerega GS,. Reduction of adhesion formation by postoperative administration of ionically cross-linked hyaluronic acid. Fertil Steril 1997; 68 (1): 37-42.
26. Henley N,. The short and unhappy history of Intergel. http://www.lawyersandsettlements.com/features/gynecare-intergel/ intergel-timeline.html, 2007.
27. Roman H, Canis M, Kamble M, Botchorishvili R, Pouly JL, Mage G,. Efficacy of three adhesion-preventing agents in reducing severe peritoneal trauma induced by bipolar coagulation in a laparoscopic rat model. Fertil Steril 2005; 83 Suppl 1: 1113-1118.
28. Tang CL, Jayne DG, Seow-Choen, Ng YY, EU KW, Mustapha N,. A randomized controlled trial of 0.5% ferric hyaluronate gel (Intergel) in the prevention of adhesions following abdominal surgery. Ann Surg 2006; 243 (4): 449-455.
29. FDA. Urgent Global Market Withdrawal: GYNECARE INTERGEL Adhesion Prevention Solution Voluntarily Withdrawn from the Market by GYNECARE Worldwide; 2003.
30. Vorvolakos K, Isayeva I, Luu H-M, Patwardhan D, Pollack S,. Ionically crosslinked hyaluronic acid: Wetting, lubrication and viscoelasticity of a modified adhesion barrier gel. Med Dev: Evid Res 2011: 1-10.
31. Takazono I, Tanaka Y,. Quantitative analysis of hyaluronic acid by high-performance liquid chromatography of streptomyces hyaluronidase digests. J Chromatogr 1984; 288 (1): 167-176.
32. Seldin DC, Seno N, Austen KF, Stevens RL,. Analysis of polysulfated chondroitin disaccharides by high-performance liquid chromatography. Anal Biochem 1984; 141 (1): 291-300.
33. Matsuno YK, Kakoi N, Kinoshita M, Matsuzaki Y, Kumada J, Kakehi K,. Electrophoresis studies on the contaminating glycosaminoglycans in commercially available hyaluronic acid products. Electrophoresis 2008; 29 (17): 3628-3635.
34. Harvey EDaW, J.M,. Preclinical guidelines for new abdominopelvic adhesion barriers. Infert Reprod Med Clin N Am 2003; 14: 481-487.
35. Noble PW,. Hyaluronan and its catabolic products in tissue injury and repair. Matrix Biol 2002; 21: 25-29.
36. Laurent TC,. Enzyme reactions in polymer media. Eur J Biochem 1971; 21 (4): 498-506.